{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.0","upperLimit":"26.8","value":"18.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"}],"units":"Participants"}],"description":"Overall survival (OS) as the interval from the on-study date until death. OS was estimated using the Kaplan Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Adult patients with MDS receive treatment with vatalanib.\n\nvatalanib: Pts registered before 1/15/05 1250 mg/day PO After 1/15/05: Start w/ 750 mg/day PO; escalate q 4 wks in absence of Grade 2 or \\> tox (1st increase=1000mg/day; 2nd increase 1250 mg/day)","id":"OG000","title":"Vatalanib"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Duration of study (up to 5 years)","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}